Charles River to make Casgevy; Rentschler extends collab with ‘major client’; Andelyn works with Ultragenyx

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Charles Riv­er Lab­o­ra­to­ries said Mon­day it will man­u­fac­ture Ver­tex and CRISPR Ther­a­peu­tics’ Cas­gevy, with its Mem­phis site hav­ing gone through au­dits by the FDA and EMA. CD­MO RoslinCT al­so man­u­fac­tures the gene edit­ing ther­a­py.

CD­MO Rentschler Bio­phar­ma said that it has a “ma­jor client” for its man­u­fac­tur­ing site in Mil­ford, MA, with the fa­cil­i­ty set to go live in the sec­ond half of next year. The man­u­fac­tur­er not­ed Wednes­day it will pro­duce its “long­stand­ing” client’s clin­i­cal-stage pro­tein ther­a­peu­tic for can­cer in the US, af­ter pre­vi­ous­ly pro­duc­ing the same as­set in Laupheim, Ger­many, for ear­ly-phase in­ves­ti­ga­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.